This is a prospective longitudinal census study conducted at a single center (DCI Inc., Henry Avenue, Philadelphia). The purpose of this study is to gain information about COVID-19 infection and antibody response in an in-center dialysis population. The investigators hypothesize that screening and surveillance for COVID-19 positive test (viral infection) and antibodies response to infection (potential immunity) in a dialysis center population within a high-prevalence region can provide foundational information to guide approaches toward prevention of COVID-19 related illness in a susceptible population. Participants will be given a questionnaire initially and monthly over the study period to find out whether they have had COVID-19 infection, hospitalization, or symptoms. A nasopharyngeal swab test for COVID-19 infection and a blood sample for COVID-19 antibody will be collected monthly for the study period.

Inclusion Criteria:

• Patients who receive in-center chronic dialysis (>3 months) at DCI Henry Avenue
• Patients who are able to consent for study

Exclusion Criteria:

• Patients receiving transient hemodialysis at DCI or receiving hemodialysis for Acute Renal Failure
• Patients who are unable to consent
• Patients who are receiving other forms of dialysis therapy (e.g. home hemodialysis, peritoneal dialysis)
• Patients whose life expectancy is <12 months
• Patients who are planning to leave the dialysis center within 12 months